Levosimendan in intensive care and emergency medicine: literature update and expert recommendations for optimal efficacy and safety
Massimo Girardis, Dominique Béttex, Miréla Bojan, Christos Demponeras, Sonja Fruhwald, János Gál, Heinrich V. Groesdonk, Fabio Guarracino, José Luis Guerrero-Orriach, Matthias Heringlake, Antoine Herpain, L M A Heunks, J. Jin, Detlef Kindgen‐Milles, Philippe Mauriat, G. Michels, V. Psallida, Stuart Rich, S-E. Ricksten, Alain Rudiger, Martin Siegemund, Wolfgang Toller, Sascha Treskatsch, Željko Župan, Piero Pollesello
Abstract
The inodilator levosimendan, in clinical use for over two decades, has been the subject of extensive clinical and experimental evaluation in various clinical settings beyond its principal indication in the management of acutely decompensated chronic heart failure. Critical care and emergency medicine applications for levosimendan have included postoperative settings, septic shock, and cardiogenic shock. As the experience in these areas continues to expand, an international task force of experts from 15 countries (Austria, Belgium, China, Croatia, Finland, France, Germany, Greece, Hungary, Italy, the Netherlands, Spain, Sweden, Switzerland, and the USA) reviewed and appraised the latest additions to the database of levosimendan use in critical care, considering all the clinical studies, meta-analyses, and guidelines published from September 2019 to November 2021. Overall, the authors of this opinion paper give levosimendan a "should be considered" recommendation in critical care and emergency medicine settings, with different levels of evidence in postoperative settings, septic shock, weaning from mechanical ventilation, weaning from veno-arterial extracorporeal membrane oxygenation, cardiogenic shock, and Takotsubo syndrome, in all cases when an inodilator is needed to restore acute severely reduced left or right ventricular ejection fraction and overall haemodynamic balance, and also in the presence of renal dysfunction/failure.